Several drugs have been investigated as an adjunct therapy for T1D, but the US FDA approved only pramlintide, which mimics a β-cell hormone that is co-secreted with insulin in the postprandial period, in 2005 (3). This evidence concerns the gene INS and type 1 diabetes mellitus.